Evidence map›Paper›PMID 33827848›Full record

Trial reportBMJ open2021

Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USA.

Devin Incerti, Shemra Rizzo, Xiao Li, Lisa Lindsay, Vincent Yau, Dan Keebler, Jenny Chia, Larry Tsai

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Hemodynamic, Oxygenation and Lymphocyte Parameters Predict COVID-19 Mortality.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Devin IncertiProduct Development, Genentech, South San Francisco, California, USA incerti.devin@gene.com.ORCID http://orcid.org/0000-0002-4479-8750
Shemra RizzoProduct Development, Genentech, South San Francisco, California, USA.
Xiao LiProduct Development, Genentech, South San Francisco, California, USA.
Lisa LindsayProduct Development, Genentech, South San Francisco, California, USA.
Vincent YauProduct Development, Genentech, South San Francisco, California, USA.
Dan KeeblerProduct Development, Genentech, South San Francisco, California, USA.
Jenny ChiaProduct Development, Genentech, South San Francisco, California, USA.
Larry TsaiProduct Development, Genentech, South San Francisco, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo develop a prognostic model to identify and quantify risk factors for mortality among patients admitted to the hospital with COVID-19.

designRetrospective cohort study. Patients were randomly assigned to either training (80%) or test (20%) sets. The training set was used to fit a multivariable logistic regression. Predictors were ranked using variable importance metrics. Models were assessed by C-indices, Brier scores and calibration plots in the test set.

settingOptum de-identified COVID-19 Electronic Health Record dataset including over 700 hospitals and 7000 clinics in the USA.

participants17 086 patients hospitalised with COVID-19 between 20 February 2020 and 5 June 2020.

main outcome measureAll-cause mortality while hospitalised.

resultsThe full model that included information on demographics, comorbidities, laboratory results, and vital signs had good discrimination (C-index=0.87) and was well calibrated, with some overpredictions for the most at-risk patients. Results were similar on the training and test sets, suggesting that there was little overfitting. Age was the most important risk factor. The performance of models that included all demographics and comorbidities (C-index=0.79) was only slightly better than a model that only included age (C-index=0.76). Across the study period, predicted mortality was 1.3% for patients aged 18 years old, 8.9% for 55 years old and 28.7% for 85 years old. Predicted mortality across all ages declined over the study period from 22.4% by March to 14.0% by May.

conclusionAge was the most important predictor of all-cause mortality, although vital signs and laboratory results added considerable prognostic information, with oxygen saturation, temperature, respiratory rate, lactate dehydrogenase and white cell count being among the most important predictors. Demographic and comorbidity factors did not improve model performance appreciably. The full model had good discrimination and was reasonably well calibrated, suggesting that it may be useful for assessment of prognosis.

Indexed as

AdolescentAdultAgedAged, 80 and overComorbidityCOVID-19FemaleHospitalizationHospital MortalityHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk FactorsUnited StatesCOVID-19epidemiologyrationingstatistics & research methods

Identifiers

PMID33827848
PMCPMC8029269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.